No peer-reviewed clinical studies, pharmacokinetic interaction data, or regulatory guidance exist on the combined use of AOD 9604 and retatrutide
Notice how your body feels
Inclusion Criteria Exclusion Criteria Timeline for a Trial Participant Screening Participants are screened for eligibility to participate in the trial Treatment Participants receive weekly subcutaneous injections of either CagriSema or Tirzepatide, with a dose escalation period followed by maintenance dosing Follow-up Participants are monitored for safety and effectiveness after treatment What Are the Treatments Tested in This Trial
The larger injection volumes make fine-tuning easier during the tirzepatide dose escalation phase
There are however several popular alternatives that are described in Notes 1 and 2
1 state for GLP-1 prescriptions in 2024 was West Virginia, followed by Kentucky, Louisiana, Oklahoma, Mississippi, North Dakota, Alaska, Arkansas and Pennsylvania, respectively